Sintilimab (PDCD1/PD1/CD279) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-919-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG4-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
IBI-308
Background:
Sintilimab is fully human anti-PD-1 antibody used for tumor immunotherapy. It adopts the IgG4 molecular framework and has its hinge region sequence modified (S228P). Sindilimum acts as a blocker of programmed death receptor 1 (PD-1), which can bind to PD-1 molecule on the surface of T cells and release the inhibitory effect of the PD-1 pathway on T cells.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Homo sapiens / PDCD1/PD1/CD279 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.